Ken Griffin Myriad Genetics Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$17.59 - $23.59 $45,734 - $61,334	-2,600 Reduced 9.15%	25,800 $550,000
Q4 2023 Feb 14, 2024	SELL	$13.91 - $21.32 $248,989 - $381,628	-17,900 Reduced 38.66%	28,400 $543,000
Q3 2023 Nov 14, 2023	BUY	$15.99 - $23.22 $481,299 - $698,922	30,100 Added 185.8%	46,300 $742,000
Q2 2023 Aug 14, 2023	SELL	$17.56 - $23.76 $1.03 Million - $1.39 Million	-58,700 Reduced 78.37%	16,200 $375,000
Q1 2023 May 15, 2023	BUY	$15.26 - $23.75 $115,976 - $180,500	7,600 Added 11.29%	74,900 $1.74 Million

Q4 2022 Feb 14, 2023	BUY	$14.51 - $20.99 $581,851 - $841,698	40,100 Added 147.43%	67,300 $976,000
Q3 2022 Nov 14, 2022	SELL	$18.21 - $27.88 $262,224 - $401,472	-14,400 Reduced 34.62%	27,200 $519,000

191

94.2M

280K

14.3K

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.97B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.